Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (platelets) | 0.10 |
| chemistry Open Targets | compounds already reach it: enokizumab | 0.81 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 8 Parkinson's papers of 2,960 | 0.71 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 7172
Sealed predictions
- IL9 in dopamine neurons, braak+0.24 (p 0.530) → +0.19 (p 0.618)receipt 7179
Swarm cases
receipt 7179: IL9 in dopamine neurons, braak
- power
- full sample +0.15 (p 0.561, n 18), 95% CI -0.34 to +0.57. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.14 (p 0.579, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.10 (p 0.690, n 18). could be the mix.
- skeptic
- leave-one-out range +0.06 to +0.29, sign flips 0; without severely affected donors +0.15 (p 0.561, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts